Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431965 | 0.92 | NPC1 (0.50) | ELANECNR1BRD4ROCK1NPC1 | |
| SCHEMBL3431593 | 0.83 | NPC1 (0.49) | ELANENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3432576 | 0.82 | ELANE (0.54) | ELANEPTGER4ROCK1NPC1RAB9A | |
| SCHEMBL3428867 | 0.81 | PTGER4 (0.46) | ELANECNR1PTGER4NPC1RAB9A | |
| SCHEMBL3432880 | 0.80 | KMT2A (0.51) | ELANENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3431330 | 0.78 | ELANE (0.53) | ELANECNR1PTGER4ROCK1NPC1 | |
| SCHEMBL3755136 | 0.75 | RAB9A (0.54) | ROCK1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3428243 | 0.74 | PTGER4 (0.52) | ELANECNR1PTGER4ROCK1NPC1 | |
| SCHEMBL13051117 | 0.73 | TRPV1 (0.44) | CNR1ROCK1PKM | |
| SCHEMBL3428314 | 0.72 | TSHR (0.55) | ELANENPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | claimed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | claimed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | claimed |
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | CPT1B, SMN1; SMN2, GYS1 | ELANE 1217/4885CNR1 2500/4885BRD4 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.